Benzinga | Aug 24, 2021 07:50AM EDT

Novartis's Kymriah Flunks In Late-Stage NHL Study

* Novartis AG's (NYSE:NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL).

* The BELINDA study included patients after relapse or lack of response to first-line treatment.

* The safety profile was consistent with the established safety profile of Kymriah.

* Novartis will complete a full evaluation of the BELINDA study data.

* Price Action: NVS shares are down 1.05% at $92.77 during the premarket session on the last check Tuesday.